Sulfonamide derivatives and their use in the treatment of CNS disorders: potent and selective antagonists at the 5-hydroxytryptamine7 receptor

Abstract

This patent discloses a novel series of 5-hydroxytryptamine₇ (5-HT₇) receptor ligands. Closely related compounds have been presented in another publication and appear to be potent and selective antagonists at recombinant 5-HT₇ receptors. These are of great pharmacological interest since it has been difficult to precisely identify and characterise functional 5-HT₇ receptors in natural tissue due to the lack of selective pharmacological tools. At present, however, it is impossible to say whether 5-HT₇ receptor antagonists such as these have any useful therapeutic indications. Further studies in animal models may help to elucidate this.

• 7 receptor
• 5-HT7 receptor antagonist
• 5-hydroxytryptamine
• circadian rhythms
• schizophrenia
• sleep disorders